SCHEMBL22189692

SCHEMBL22189692

COC(=O)c1ccncc1Cc1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.56
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GLA P06280 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 2/20 0.42
TP53 P04637 1/20 0.42
GRM2 Q14416 1/20 0.42
POLB P06746 1/20 0.42
HSP90AA1 P07900 2/20 0.41
HSP90B1 P14625 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
LMNA P02545 2/20 0.41
NPC1 O15118 1/20 0.41
CASP3 P42574 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22189724 0.88 L3MBTL1 (0.55) L3MBTL1ALDH1A1KDM4EGLAGAA
SCHEMBL6269745 0.84 KDM4E (0.48) L3MBTL1ALDH1A1KDM4EGLAGAA
SCHEMBL7519629 0.84 CYP11B1 (0.51) L3MBTL1ALDH1A1KDM4EGLAGAA
SCHEMBL22189609 0.82 KDM4C (0.45) L3MBTL1ALDH1A1KDM4EGAAMAPT
SCHEMBL29581046 0.82 KDM4C (0.45) L3MBTL1ALDH1A1KDM4EGAAMAPT
SCHEMBL22189659 0.80 ALDH1A1 (0.49) L3MBTL1ALDH1A1KDM4EGLAGAA
SCHEMBL17610282 0.79 L3MBTL1 (0.45) L3MBTL1ALDH1A1KDM4EGLAGAA
SCHEMBL22189722 0.79 L3MBTL1 (0.52) L3MBTL1ALDH1A1KDM4EGLAGAA
SCHEMBL845125 0.79 ALDH1A1 (0.62) L3MBTL1ALDH1A1KDM4EGLAGAA
SCHEMBL15839871 0.78 KDM4C (0.56) L3MBTL1ALDH1A1KDM4EGLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114126597-A Fibroblast activation protein inhibitor 普拉西斯生物技术有限责任公司 2022-03-01 CN disclosed
EP-3906024-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2021-11-10 EP disclosed
US-20200216417-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2020-07-09 US disclosed
WO-2020142742-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2020-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216417-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FAP, FIBP, FRS2 L3MBTL1 4163/4885ALDH1A1 3702/4885KDM4E 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.